# Orionis Biosciences: Research, Waltham, United States

> Orionis Biosciences: Orionis Biosciences is a clinical-stage life sciences company based in Waltham, Massachusetts, with a research facility in Ghent, Belgium.

Source: https://millionrounds.com/startup/orionis-biosciences (Millionrounds; every figure on the page links to its filing or article)

United States · [Research startup](https://millionrounds.com/companies)

# Orionis Biosciences

Orionis Biosciences is a clinical-stage life sciences company based in Waltham, Massachusetts, with a research facility in Ghent, Belgium.

Email

Funding reported Last round: Series C

Research Waltham, United States

Follow Orionis Biosciences and see its new rounds in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Fstartup%2Forionis-biosciences)

Company summary

- **Founded:** 2015 11 years old
- **Team:** 69 51 to 200 people
- **Funding reported:** $79M in dollars
- **Last round:** Series C Oct 2022

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Orionis Biosciences has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Orionis Biosciences

Orionis Biosciences is a clinical-stage life sciences company based in Waltham, Massachusetts, with a research facility in Ghent, Belgium.

Founded in 2015, the company focuses on discovering and engineering conditionally active drug modalities that target disease-driving processes and activate immune responses. Orionis specializes in translational drug discovery, utilizing innovative technologies to enhance drug potency and precision for life-threatening diseases, particularly in cancer and immunology. The company operates two proprietary platforms: A-KineTM, which creates conditionally active immunotherapies with high cell target selectivity, and Allo-GlueTM, a small-molecule platform for molecular glue drug discovery. Orionis has a robust drug discovery pipeline, including two cancer immunotherapy drugs in clinical trials and several advanced preclinical programs. The company collaborates with strategic pharmaceutical partners like Novartis and Genentech/Roche, while also targeting patients with advanced diseases through its internal clinical programs. Orionis has raised significant funding and continues to advance its mission in the life sciences sector.

## What company datasets say Orionis Biosciences raised

Funding, as reported

Reported in all **$79M** in dollars

Rounds **7**

Last round **Series C**

Last round size **$55M**

Last round date **Oct 2022**

Investors listed **8**

SEC Form D **$24M sold, 3 filings, last Apr 2018**

## Founders and team

From the SEC filings it signed: 3 on the team.

- **Griet R. Vanpoucke** Manager i
- **Nikolai Kley** Manager i
- **Steven R. Gullans** Manager i

## On 4 portfolio pages

Investors who name them

- [Solasta Ventures](https://millionrounds.com/fund/solasta-ventures)
- [Empire Angels](https://millionrounds.com/fund/empire-angels)
- [V-Bio Ventures](https://millionrounds.com/fund/v-bio-ventures)
- [Solari Capital](https://millionrounds.com/fund/solari-capital)

Each firm lists Orionis Biosciences on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

health care biologics platform immune signaling biotechnology research conditional cytokines multimodal cell engagers therapeutic modalities medical research collaborations with pharma immune cell engagement computational science biotech collaborations chemical biology protein engineering hospital & health care immune synapse engineering

Built with from their website

Google Maps Google Tag Manager WordPress.org CloudFlare Viewport Meta Cloudflare WAF Google Maps Platform CloudFlare CDN Priority Hints Sucuri

+8 more

Microsoft Exchange MySQL PrimeNG Microsoft 365 Apps & Services Mobile Friendly Open Graph jQuery Anthropic Claude

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 2834
- **Region:** Massachusetts
- **Revenue:** $6.5M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/orionis-biosciences)

## Research in United States

Startups like it

- [**OpenAI** San Francisco · founded 2011 *Raised*](https://millionrounds.com/company/openai)
- [**Retro Biosciences** Redwood City · founded 2021 *Raised*](https://millionrounds.com/company/retro-biosciences)
- [**NewLimit** South San Francisco · founded 2022 *Raised*](https://millionrounds.com/company/newlimit)
- [**Pathos** New York · founded 2022 *Raised*](https://millionrounds.com/company/pathos)
- [**Colossal Biosciences** Dallas · founded 2021 *Raised*](https://millionrounds.com/company/colossal-biosciences)
- [**Oratomic** South Pasadena *Raised*](https://millionrounds.com/company/oratomic)
- [**Beeline Medicines** Stamford · founded 2025 *Raised*](https://millionrounds.com/company/beeline-medicines)
- [**Element Biosciences** San Diego · founded 2017 *Raised*](https://millionrounds.com/company/element-biosciences)

## Is this your company?

Add your raise, your deck and your story, and put Orionis Biosciences in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)